ANTX
AN2 Therapeutics, Inc.NASDAQHealthcare$3.27-5.22%ClosedMarket Cap: $89.6M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.92
P/S
0.00
EV/EBITDA
-1.90
DCF Value
$0.59
FCF Yield
-32.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-55.0%
ROA
-56.8%
ROIC
-71.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-8.7M | $-0.29 |
| FY 2025 | $0.00 | $-35.2M | $-1.16 |
| Q3 2025 | $0.00 | $-9.4M | $-0.31 |
| Q2 2025 | $0.00 | $-6.5M | $-0.21 |
Analyst Ratings
View AllJMP SecuritiesMarket Outperform
2025-05-05Trading Activity
Insider Trades
View AllDay Lucyofficer: Chief Financial Officer
SellMon Mar 23
Day Lucyofficer: Chief Financial Officer
SellMon Mar 23
Day Lucyofficer: Chief Financial Officer
SellMon Mar 23
Day Lucyofficer: Chief Financial Officer
SellMon Mar 23
Day Lucyofficer: Chief Financial Officer
SellMon Mar 23
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-1.32
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.